Samsung Bioepis has struck a US settlement with Johnson & Johnson that will allow partner Sandoz to launch the pair’s SB17 ustekinumab biosimilar to Stelara in early 2025, assuming FDA approval.
Samsung Bioepis has announced a settlement with Johnson & Johnson that will allow the Korean firm’s US marketing partner Sandoz to launch the pair’s partnered SB17 biosimilar to Stelara (ustekinumab) from 22 February 2025.
While the biosimilar has not yet been approved by the US Food and Drug Administration, Samsung Bioepis said the settlement and license agreement with J&J settles “all pending US patent litigation between
Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.
Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.
Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.
